<a href="https://www.fiercebiotech.com/biotech/novo-ceo-insists-no-change-plan-cagrisema-launch-after-single-chamber-device-ditched" hreflang="en">Novo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditched</a>
Novo Nordisk's CEO has confirmed that the launch plans for the GLP-1/amylin combo treatment CagriSema remain unchanged, despite the termination of a project for a single-chamber delivery device. The company is still on track for U.S. approval by the end of 2023 and anticipates launching the product in early 2027, while also progressing with another treatment, zenagamtide, for obesity.
Novo Nordisk's commitment to launching CagriSema, a GLP-1/amylin combo treatment, despite abandoning a single-chamber delivery device, highlights a strategic shift toward prioritizing their dual-chamber system. This decision, alongside the progress in phase 3 studies of zenagamtide, underscores Novo's focus on maintaining a competitive edge in the obesity treatment market. For professionals tracking healthtech and biotech advancements, this signals a resilient strategy in drug delivery innovation and market positioning amidst competitive pressures.